Enhanced immunogenicity of a bivalent nicotine vaccine

International Immunopharmacology

Volumn 8, Issue 11, 2008, Pages 1589-1594

  Keyler, D E ^a,b   Roiko, S A ^c   Earley, C A ^a   Murtaugh, M P ^c   Pentel, P R ^a,b,d  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Antibody; Bivalent; Immunogenicity; Immunotherapy; Nicotine; Vaccine

Indexed keywords

3' AMINOMETHYLNICOTINE PSEUDOMONAS EXOPROTEIN A CONJUGATE; 6 CARBOXYMETHYLUREIDONICOTINE KEYHOLE LIMPET HEMOCYANIN CONJUGATE; ANTIBODY; FREUND ADJUVANT; NICOTINE; NICOTINE ANTIBODY; NICOTINE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG POTENTIATION; IMMUNOGENICITY; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; SMOKING CESSATION; VACCINE PRODUCTION;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CROSS REACTIONS; HEMOCYANIN; NICOTINE; RATS; SMOKING; SMOKING CESSATION; VACCINATION; VACCINES, CONJUGATE;

EID: 51749104142     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.07.001     Document Type: Article

References (32)

1. U.S. Department of Health and Human Services. Nicotine addiction: health consequences of smoking (1999), DHHS
2. Vocci F.J., and Chiang C.N. Vaccines against nicotine: how effective are they likely to be in preventing smoking?. CNS Drugs 15 (2001) 505-514
3. Pentel P.R., LeSage M.G., Keyler D.E., and Hatsukami D.E. Immunologic approaches to nicotine addiction. In: George T.P. (Ed). Medication treatments for nicotine dependence (2007), Taylor & Francis, New York 151-166
4. Maurer P., Jennings G.T., Willers J., et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity. Eur J Immunol 35 (2005) 2031-2040
5. Satoskar S.D., Keyler D.E., LeSage M.G., Raphael D.E., Ross C.A., and Pentel P.R. Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. Int Immunopharmacol 3 (2003) 957-970
6. de Villiers S.H., Lindblom N., Kalayanov G., Gordon S., Johansson A.M., and Svensson T.H. Active immunization against nicotine alters the distribution of nicotine but not the metabolism to cotinine in the rat. Naunyn Schmiedebergs Arch Pharmacol 370 (2004) 299-304
7. Cerny E.H., Levy R., Mauel J., et al. Preclinical development of a vaccine 'against smoking'. Onkologie 25 (2002) 406-411
8. Carrera M.R., Ashley J.A., Hoffman T.Z., et al. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem 12 (2004) 563-570
9. Malin D.H., Alvarado C.L., Woodhouse K.S., et al. Passive immunization against nicotine attenuates nicotine discrimination. Life Sci 70 (2002) 2793-2798
10. LeSage M.G., Keyler D.E., Hieda Y., et al. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology (Berl) 184 (2006) 409-416
11. Lindblom N., De Villiers S.H., Kalayanov G., Gordon S., Johansson A.M., and Svensson T.H. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 69 (2002) 254-260
12. Hieda Y., Keyler D.E., VanDeVoort J.T., et al. Immunization of rats reduces nicotine distribution to brain. Psychopharmacology 143 (1999) 150-157
13. Keyler D.E., Roiko S.A., Benlhabib E., et al. Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships. Drug Metab Dispos 33 (2005) 1056-1061
14. Hatsukami D.K., Rennard S., Jorenby D., et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 78 (2005) 456-467
15. Maurer P., and Bachmann M.F. Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs 16 (2007) 1775-1783
16. McNeil C. Nicotine vaccines move toward pivotal trials. J Natl Cancer Inst 98 (2006) 301
17. ® demonstrated proof of concept at 6 months, an evaluation of a conjugate nicotine vaccine in smokers who want to quit. Eur Soc Res Nicotine Tob (Oct 2007) Madrid, Spain
18. Pentel P.R., Malin D.H., Ennifar S., et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 65 (2000) 191-198
19. Hieda Y., Keyler D.E., Vandevoort J.T., et al. Active immunization alters the plasma nicotine concentration in rats. J Pharmacol Exp Ther 283 (1997) 1076-1081
20. Muller R. Determination of affinity and specificity of anti-hapten antibodies by competitive radioimmunoassay. Methods of Enzymology 92 (1983) 589-601
21. Jacob P., Wilson M., and Benowitz N.L. Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. J Chromatog 222 (1981) 61-70
22. Rennels M.B., Lagos R.M., and Edwards K.M. Combination vaccines for routine infant immunization. In: Levine M.M., Kaper J.B., Rappuoli R., Liu M.A., and Good M.F. (Eds). New generation vaccines. 3rd ed (2004), Marcel Dekker, Inc., New York 413-419
23. Greenberg D.P., Wong V.K., Partridge S., et al. Immunogenicity of a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine. Pediatr Infect Dis J 19 (2000) 1135-1140
24. Halperin S.A., Langley J.M., and Eastwood B.J. Effect of inactivated poliovirus vaccine on the antibody response to Bordetella pertussis antigens when combined with diphtheria-pertussis-tetanus vaccine. Clin Infect Dis 22 (1996) 59-62
25. Andre F.E., and Peetermans J. Effect of simultaneous administration of live measles vaccine on the "take rate" of live mumps vaccine. Dev Biol Stand 65 (1986) 101-107
26. Corkill J.M. The stability of the components in DTP-poliomyelitis and DPT-poliomyelitis-measles vaccines. Symposia Series in Immunological Standardization (1967), Karger, Basel 165-178
27. Mulupuri P., Zimmerman J., Hermann J., et al. Antigen-specific B-cell responses to porcine reproductive and respiratory syndrome virus infection. J Virology 82 (2008) 358-370
28. Castro A., Monji N., Ali H., Yi M., Bowman E.R., and McKennis Jr. H. Nicotine antibodies: comparison of ligand specificities of antibodies produced against two nicotine conjugates. Eur J Biochem 104 (1980) 331-340s
29. Kosten T.R., Gonsai K., St Clair Roberts J., et al. Phase II human study of cocaine vaccine TA-CD (2002), CPDD Annual Meeting, Quebec City
30. O'Brien K.L., Moisi J., Moulton L.H., et al. Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial. J Infect Dis 196 (2007) 104-114
31. Poland G.A., Ovsyannikova I.G., Jacobson R.M., and Smith D.I. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther 82 (2007) 653-664
32. Alving C.R. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 20 Suppl 3 (2002) S56-64